Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis
NCT: NCT06940427 · RECRUITING
Brief Summary
The goal of this clinical trial is to gain more information about how fibroblast activation protein inhibitor (FAPI) binds to a certain type of cells in fibrotic lung tissue and how this information can be used to better diagnose and track fibrotic lung disease activity. Participants will undergo up to 4 PET/MRI scans using the FAPI radiotracer.
Frequently Asked Questions
What is Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis?
Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis is a clinical trial registered under NCT06940427. Current status: RECRUITING.
What is the status of NCT06940427?
The current status of NCT06940427 (Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis) is: RECRUITING.
When did Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis start?
Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis started on 2025-11-19.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.